Clinical Trial Update: B7-H3 CAR-T for Recurrent or Refractory Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating B7-H3 CAR-T cells for recurrent or refractory glioblastoma is reported as ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• B7-H3 CAR T (B7-H3 targeted CAR T)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Recurrent Glioblastoma, Refractory Glioblastoma | Phase 1, Phase 2 | Status: UNKNOWN